Zobrazeno 1 - 10
of 164
pro vyhledávání: ''
Autor:
Jia-Jun, Wu, Jing-Wen, Huang, Kuo-Hsuan, Hsu, Yen-Hsiang, Huang, Kun-Chieh, Chen, Jeng-Sen, Tseng, Tsung-Ying, Yang, Gee-Chen, Chang
Publikováno v:
Anti-Cancer Drugs. 33:e842-e849
Immunotherapy plus etoposide and platinum (EP)-based chemotherapy is the standard of care for patients with extensive stage-small cell lung carcinoma (ES-SCLC). In the era of immunotherapy, the role of thoracic radiotherapy for ES-SCLC remains unclea
Autor:
Satoshi, Fukata, Keisuke, Mizutani, Shinkuro, Yamamoto, Takahira, Kuno, Hideo, Fukuhara, Shingo, Ashida, Takashi, Karashima, Keiji, Inoue
Publikováno v:
Anti-Cancer Drugs. 33:459-466
The objective was to evaluate the usefulness of sarcopenia and the neutrophil/lymphocyte ratio (NLR) as therapeutic efficacy predictors in patients who received pembrolizumab after platinum-based chemotherapy for advanced urothelial carcinoma (aUC).
Publikováno v:
Anti-cancer drugs. 33(10)
Gastric cancer (GC) is a common digestive system malignancy. The aim of this study was to explore the role of Delta/Notch-like epidermal growth factor-related receptor (DNER) in GC patients and cells. Gene expression omnibus data base public database
Publikováno v:
Anti-cancer drugs. 33(10)
The aim of this study was to investigate the predictive value of PLR and NLR as an indicator of pathological complete response (pCR) in patients with breast cancer after NACT. One hundred thirty-nine patients with early or LABC and candidates to NACT
Publikováno v:
Anti-Cancer Drugs
OBJECTIVE A retrospective study was conducted to analyze which translational therapy, palliative chemotherapy and surgery is the best treatment for locally advanced and advanced pancreatic cancer, and to screen out the dominant population for the bes
Publikováno v:
Anti-Cancer Drugs. 33:e534-e540
We aimed to assess the prognostic and predictive significance of pretreatment Prognostic Nutritional Index (PNI) in extensive-stage small-cell lung cancer (ES-SCLC) patients treated with first-line chemotherapy. We designed this study to evaluate the
Publikováno v:
Anti-Cancer Drugs. 33:e584-e589
This retrospective study was conducted to explore the effects of anlotinib as first-line treatment for patients with advanced lung adenocarcinoma. We retrospectively reviewed medical records of 60 patients with advanced lung adenocarcinoma, admitted
Autor:
Cuizhen Liu, Xinping Ye, Yanfeng Jiang, Guangzhi Zhu, Jing Tang, Tao Peng, Jie Ma, Zhiming Zeng, Jie Zeng, Fuchao Ma, Jinfeng Qiu, Lihua Yang
Publikováno v:
Anti-Cancer Drugs. 32:1093-1098
This study was to explore the efficacy and safety of camrelizumab combined with apatinib in patients with advanced liver cancer. Moreover, the relationship between peripheral blood parameters and tumor response rate was also investigated. Patients wi
Autor:
Tianwen Gao, Yanhong Zhao, Lei Wang, Tao Zhao, Weinan Guo, Guannan Zhu, Weigang Zhang, Qiong Shi, Lin Liu, Chunying Li, Yu Liu, Jianhong Zhao
Publikováno v:
Anti-Cancer Drugs. 32:1105-1110
Objectives Recombinant human interferon-α1b (IFN-α1b) is the first genetic engineered drug of China and is approved for cancer treatment by Chinese Food and Drug Administration. Although recombinant IFN-α1b is biologically and therapeutically acti
Publikováno v:
Anti-Cancer Drugs. 32:882-885
Erlotinib is a tyrosine kinase inhibitor that inhibits epidermal growth factor receptor. It is being used for metastatic non-small cell lung cancer patients (NSCLC). Repurposing noncancer drugs for cancer treatment is a current issue and it has many